Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988205 · ClinicalTrials.gov registry record · Phase 4
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
A Phase 4 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03988205: Clinical Trial Phase 4 study, sponsored by Medical College of Wisconsin.
NCT03988205 is a Phase 4 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03988205, a Phase 4 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter continuation phase (114 subjects), Phase IV study. Eligible subjects will be receiving CPX-351 as their usual medical care administered according to FDA approval, as a condition for participation.
Primary Outcome
This measure will record the number subjects who adhere to outpatient follow-up appointments and readmission recommendations. Subjects completing 95% of their recommended outpatient visits will be considered to be adherent to the recommendations.
Interventions
- DRUG CPX-351
- BEHAVIORAL Outpatient Care Model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-28 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 4 |
Why NCT03988205 stopped before completion
NCT03988205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which CPX-351 is the first listed.
NCT03988205 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03988205 about?
NCT03988205 is a clinical study titled "Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia". This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter continuation phase (114 subjects), Phase IV study. Eligible subjects will be receiving CPX-351 as their usual medical care administered according to FDA approval, as a condition for participation.
What is the current status of trial NCT03988205?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2019-08-28. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT03988205?
The interventions under investigation include: CPX-351 (DRUG), Outpatient Care Model (BEHAVIORAL).
Who is sponsoring clinical trial NCT03988205?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03988205's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI